Meanwhile, it will be interesting to see whether known transcription factors that regulate AXL synthesis (i.e., activator protein AP1, YAP/TAZ/TEAD, and HIF1α) can mediate the predominant activation AXL and promote EGFR-TKI-specific resistance trajectory in chemoresistant cancer cells. The gene discussed is AXL; the disease is cancer.